Multi4 Medical Publishes Landmark Study in BJUI, Initiates First Patient Treatments in Europe
News related to:Multi4 Medical · 2 min read
Multi4 Medical, a Swedish medical technology company, has published groundbreaking clinical research in the prestigious British Journal of Urology International (BJUI).
The research details the development and clinical validation of the Multi4 System, a single, integrated instrument designed to perform both therapeutic treatment and diagnostic tissue sampling in a single, rapid outpatient procedure. The study was conducted at Sahlgrenska University Hospital, led by Dr. Henrik Kjölhede, in collaboration with Joakim Håkansson from RISE (Research Institutes of Sweden).
The Multi4 System features a 2 mm micro-instrument with a highly integrated, patented design. During a standard outpatient visit, the urologist can use this single tool to apply local anesthesia, precisely resect the cancer tissue, automatically extract and retrieve the tissue samples for pathology analysis, and perform coagulation and ablation to control bleeding as needed. The entire procedure is performed on an awake patient in a matter of minutes, eliminating the need for general anesthesia, operating rooms, or hospitalization.
This innovation has the potential to revolutionize bladder cancer care by moving treatment from the operating room to the outpatient clinic. The study, which evaluated 18 patients with recurrent NMIBC, demonstrated outstanding safety and procedural success. The results confirm that patients can be treated immediately upon cancer detection, reducing anxiety and eliminating the risks associated with general anesthesia. Additionally, the procedure allows for same-day discharge and minimizes the risk of complications.
The publication of this study in BJUI, one of the world's most prestigious and high-impact urology journals, coincides with the initiation of the first patient treatments in Sweden. Multi4 Medical received its CE-mark approval earlier this year, enabling the company to begin treating patients in the clinic. The company has also secured FDA clearance for the US market, setting the stage for a parallel expansion in the United States.
Dr. Miden Melle-Hannah, the urologist, founder, and CEO of Multi4 Medical, expressed excitement about the milestone. "Having our peer-reviewed data published in BJUI at the exact moment we begin treating patients in the clinic is a spectacular milestone. It proves what is possible when disruptive innovation creates immediate value for all stakeholders: patients receive faster and safer care, urologists gain a vastly superior tool, and the healthcare system achieves unprecedented operational efficiency and cost savings."
The Multi4 System is expected to have a significant impact on the healthcare system. By reducing the need for general anesthesia and operating rooms, the technology can help alleviate OR waitlists, reduce costs per procedure, and increase clinical throughput. Multi4 Medical is currently working to expand its operations in the United States, where shifting procedures out of the expensive OR setting is a major economic driver for payors and providers.
The company's flagship product, the Multi4 System, is a patented, automated system for cancer diagnostics and treatment. It revolutionizes bladder cancer care by moving treatment from the operating room to the outpatient clinic. Multi4 Medical is a portfolio company of real estate magnate Erik Selin, alongside a syndicate of highly respected, active medtech investors, including Fredrik Strömholm, Per Langö, Emil Billbäck, Erik Gatenholm, and Ulf Rosén. The proprietary platform technology is highly scalable and is currently being developed for application in other cancer indications.